AR-2201

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAR-2201
Drug Alias NameAR-2201
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesDana-Farber Cancer Institute
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A